Table 1. Open in new tab Patient... | Oxford Academic

Table 1.

Open in new tab

Patient Characteristics, Infectious Dose, Route of Infection, and Prepatent Period

Patient Identifier	Patient Age, y	Patient Sex	Dose, PfSPZ/Route	Prepatent Period, d^a
2500.1	22	Female	2500/Intradermal	15
2500.2	21	Male	2500/Intradermal	14
2500.3	42	Male	2500/Intradermal	13
50.1	27	Male	50/Intravenous	13
200.1	27	Male	200/Intravenous	14
800.1	29	Male	800/Intravenous	11
800.2	28	Male	800/Intravenous	11
800.3	22	Male	800/Intravenous	12
800.4	24	Female	800/Intravenous	12
800.5	25	Male	800/Intravenous	12
3200.2	27	Male	3200/Intravenous	11
3200.3	26	Male	3200/Intravenous	11
3200.4	30	Female	3200/Intravenous	11
3200.5	28	Male	3200/Intravenous	11
3200.6	28	Male	3200/Intravenous	11
3200.7	24	Male	3200/Intravenous	10
3200.8	25	Male	3200/Intravenous	11
3200.9	27	Female	3200/Intravenous	12

Patient Identifier	Patient Age, y	Patient Sex	Dose, PfSPZ/Route	Prepatent Period, d^a
2500.1	22	Female	2500/Intradermal	15
2500.2	21	Male	2500/Intradermal	14
2500.3	42	Male	2500/Intradermal	13
50.1	27	Male	50/Intravenous	13
200.1	27	Male	200/Intravenous	14
800.1	29	Male	800/Intravenous	11
800.2	28	Male	800/Intravenous	11
800.3	22	Male	800/Intravenous	12
800.4	24	Female	800/Intravenous	12
800.5	25	Male	800/Intravenous	12
3200.2	27	Male	3200/Intravenous	11
3200.3	26	Male	3200/Intravenous	11
3200.4	30	Female	3200/Intravenous	11
3200.5	28	Male	3200/Intravenous	11
3200.6	28	Male	3200/Intravenous	11
3200.7	24	Male	3200/Intravenous	10
3200.8	25	Male	3200/Intravenous	11
3200.9	27	Female	3200/Intravenous	12

Abbreviation: PfSPZ, Plasmodium falciparum sporozoites.

^a The prepatent period is the time from infection to the first positive thick blood smear (in days).

Table 1.

Open in new tab

Patient Characteristics, Infectious Dose, Route of Infection, and Prepatent Period

Patient Identifier	Patient Age, y	Patient Sex	Dose, PfSPZ/Route	Prepatent Period, d^a
2500.1	22	Female	2500/Intradermal	15
2500.2	21	Male	2500/Intradermal	14
2500.3	42	Male	2500/Intradermal	13
50.1	27	Male	50/Intravenous	13
200.1	27	Male	200/Intravenous	14
800.1	29	Male	800/Intravenous	11
800.2	28	Male	800/Intravenous	11
800.3	22	Male	800/Intravenous	12
800.4	24	Female	800/Intravenous	12
800.5	25	Male	800/Intravenous	12
3200.2	27	Male	3200/Intravenous	11
3200.3	26	Male	3200/Intravenous	11
3200.4	30	Female	3200/Intravenous	11
3200.5	28	Male	3200/Intravenous	11
3200.6	28	Male	3200/Intravenous	11
3200.7	24	Male	3200/Intravenous	10
3200.8	25	Male	3200/Intravenous	11
3200.9	27	Female	3200/Intravenous	12

Patient Identifier	Patient Age, y	Patient Sex	Dose, PfSPZ/Route	Prepatent Period, d^a
2500.1	22	Female	2500/Intradermal	15
2500.2	21	Male	2500/Intradermal	14
2500.3	42	Male	2500/Intradermal	13
50.1	27	Male	50/Intravenous	13
200.1	27	Male	200/Intravenous	14
800.1	29	Male	800/Intravenous	11
800.2	28	Male	800/Intravenous	11
800.3	22	Male	800/Intravenous	12
800.4	24	Female	800/Intravenous	12
800.5	25	Male	800/Intravenous	12
3200.2	27	Male	3200/Intravenous	11
3200.3	26	Male	3200/Intravenous	11
3200.4	30	Female	3200/Intravenous	11
3200.5	28	Male	3200/Intravenous	11
3200.6	28	Male	3200/Intravenous	11
3200.7	24	Male	3200/Intravenous	10
3200.8	25	Male	3200/Intravenous	11
3200.9	27	Female	3200/Intravenous	12

Abbreviation: PfSPZ, Plasmodium falciparum sporozoites.

^a The prepatent period is the time from infection to the first positive thick blood smear (in days).